Toward Type I/II ROS Generation Photoimmunotherapy by Molecular Engineering of Semiconducting Perylene Diimide

Author:

Zhang Jie1,Ma Wen1,Luo Haifen1,Zhang Kangxin1,Lv Jingqi1,Jiang Lizhi1,Huang Yanli1,Song Jibing2,Yang Zhen1,Huang Wei13ORCID

Affiliation:

1. Strait Laboratory of Flexible Electronics (SLoFE) Strait Institute of Flexible Electronics (SIFE Future Technologies) Fujian Normal University Fuzhou Fujian 350117 P. R. China

2. State Key Laboratory of Chemical Resource Engineering College of Chemistry Beijing University of Chemical Technology Beijing 100029 P. R. China

3. Frontiers Science Center for Flexible Electronics (FSCFE) MIIT Key Laboratory of Flexible Electronics (KLoFE) Northwestern Polytechnical University Xi'an 710072 P. R. China

Abstract

AbstractAs prospective phototheranostic agents for cancer imaging and therapy, semiconducting organic molecule‐based nanomedicines are developed. However, near‐infrared (NIR) emission, and tunable type I (O2) and type II (1O2) photoinduced reactive oxygen species (ROS) generation to boost cancer photoimmunotherapy remains a big challenge. Herein, a series of D–π–A structures, NIR absorbing perylene diimides (PDIs) with heavy atom bromide modification at the bay position of PDIs are prepared for investigating the optimal photoinduced type I/II ROS generation. The heavy atom effect has demonstrated a reduction of molecular ∆EST and promotion of the intersystem crossing processes of PDIs, enhancing the photodynamic therapy (PDT) efficacy. The modification of three bromides and one pyrrolidine at the bay position of PDI (TBDT) has demonstrated the best type I/II PDT performance by batch experiments and theoretical calculations. TBDT based nanoplatforms (TBDT NPs) enable type I/II PDT in the hypoxic tumor microenvironment as a strong immunogenic cell death (ICD) inducer. Moreover, TBDT NPs showing NIR emission allow in vivo bioimaging guided phototherapy of tumor. This work uses novel PDIs with adjustable type I/II ROS production to promote antitumor immune response and accomplish effective tumor eradication, consequently offering molecular guidelines for building high‐efficiency ICD inducers.

Funder

National Natural Science Foundation of China

Natural Science Foundation of Fujian Province

Publisher

Wiley

Subject

Pharmaceutical Science,Biomedical Engineering,Biomaterials

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3